News
DRRX
1.670
+1.21%
0.020
Weekly Report: what happened at DRRX last week (0715-0719)?
Weekly Report · 4d ago
Weekly Report: what happened at DRRX last week (0708-0712)?
Weekly Report · 07/15 12:03
Weekly Report: what happened at DRRX last week (0701-0705)?
Weekly Report · 07/08 12:05
Weekly Report: what happened at DRRX last week (0624-0628)?
Weekly Report · 07/01 12:06
Weekly Report: what happened at DRRX last week (0617-0621)?
Weekly Report · 06/24 12:16
Weekly Report: what happened at DRRX last week (0610-0614)?
Weekly Report · 06/17 12:04
Weekly Report: what happened at DRRX last week (0603-0607)?
Weekly Report · 06/10 12:07
Northland Securities Remains a Buy on Durect (DRRX)
TipRanks · 06/04 12:46
Weekly Report: what happened at DRRX last week (0527-0531)?
Weekly Report · 06/03 12:11
Weekly Report: what happened at DRRX last week (0520-0524)?
Weekly Report · 05/27 12:17
Analysts Are Bullish on Top Healthcare Stocks: Guardant Health (GH), Durect (DRRX)
TipRanks · 05/22 13:00
H.C. Wainwright Remains a Hold on Durect (DRRX)
TipRanks · 05/22 10:27
HC Wainwright & Co. Reiterates Neutral on Durect
Benzinga · 05/22 10:26
12 Health Care Stocks Moving In Tuesday's After-Market Session
Rezolute stock increased by to $ during Tuesday's after-market session. The company's market cap stands at $ million. Rezolute is one of a number of stocks to move upwards in the after- market session. MyMD Pharmaceuticals (NASDAQ:MYMD) shares increased by $ during the session.
Benzinga · 05/21 20:31
BUZZ-U.S. STOCKS ON THE MOVE-ProShares Ether, International Business Machines, Alvotech
The main indexes oscillated within a tight range on Tuesday. Investors grew cautious ahead of AI chip leader Nvidia's earnings this week. Federal Reserve officials emphasized the central bank was in hurry to ease interest rates. At 13:44 ET, the Dow Jones Industrial Average and the S&P 500 were up.
Reuters · 05/21 18:18
Health Care Sector Update for 05/21/2024: PFE, EXAI, DRRX
NASDAQ · 05/21 17:55
BUZZ-U.S. STOCKS ON THE MOVE-Durect, Mangoceuticals, International Business Machines
The tech-heavy Nasdaq fell on Tuesday as investors grew cautious ahead of AI chip leader Nvidia's earnings this week. Federal Reserve officials emphasized the central bank is in hurry to ease interest rates. The Dow Jones Industrial Average and the S&P 500 were up on Tuesday.
Reuters · 05/21 16:19
BUZZ-Durect up on FDA's 'breakthrough therapy' tag for liver disease treatment
Durect Corp up on FDA's 'breakthrough therapy' tag for liver disease treatment for severe alcohol-associated hepatitis. Company's stock up more than 80% YTD. FDA has granted DRRX's treatment for patients with severe alcohol associated hepatitis a rare form of liver disease.
Reuters · 05/21 14:17
DURECT gets FDA breakthrough therapy status for larsucosterol
Healthcare DURECT gets FDA breakthrough therapy status for larsucosterol in the treatment of severe alcohol-related hepatitis. The drug developer plans to present additional details on Phase 2 data for the drug at the European Association for the Study of the Liver Congress in June.
Seeking Alpha · 05/21 14:10
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Biodexa Pharmaceuticals (NASDAQ:BDRX) shares increased by to $ during Tuesday's pre-market session. The company's Q1 earnings report came out 4 days ago. BiodexA Pharmaceuticals is one of a number of companies in the biotechnology sector.
Benzinga · 05/21 12:06
More
Webull provides a variety of real-time DRRX stock news. You can receive the latest news about DURECT through multiple platforms. This information may help you make smarter investment decisions.
About DRRX
DURECT Corporation is a late-stage biopharmaceutical company pioneering the development of epigenetic therapies that target dysregulated deoxyribonucleic acid (DNA) methylation to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer. Larsucosterol is in clinical development for the potential treatment of alcohol-associated hepatitis, for which United States Food and Drug Administration (FDA) has granted a Fast Track Designation; metabolic dysfunction-associated steatohepatitis is also being explored. Its commercial pharmaceutical products include POSIMIR (bupivacaine solution), PERSERIS (schizophrenia) and Methydur Sustained Release Capsules (ADHD). POSIMIR (bupivacaine solution) for infiltration use, a non-opioid analgesic utilizing the SABER platform technology, is FDA-approved. Its ALZET product line consists of miniature, implantable osmotic pumps and accessories used for research in mice, rats and other laboratory animals.